BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33283275)

  • 1. IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.
    Siddiqui S; Hackl S; Ghoddusi H; McIntosh MR; Gomes AC; Ho J; Reeves MB; McLean GR
    Immunology; 2021 Mar; 162(3):314-327. PubMed ID: 33283275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
    Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
    Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
    Baraniak I; Gomes AC; Sodi I; Langstone T; Rothwell E; Atkinson C; Pichon S; Piras-Douce F; Griffiths PD; Reeves MB
    EBioMedicine; 2019 Dec; 50():45-54. PubMed ID: 31735553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a neutralizing epitope within antigenic domain 5 of glycoprotein B of human cytomegalovirus.
    Wiegers AK; Sticht H; Winkler TH; Britt WJ; Mach M
    J Virol; 2015 Jan; 89(1):361-72. PubMed ID: 25320309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.
    Baraniak I; Kropff B; McLean GR; Pichon S; Piras-Douce F; Milne RSB; Smith C; Mach M; Griffiths PD; Reeves MB
    J Infect Dis; 2018 May; 217(12):1907-1917. PubMed ID: 29528415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
    Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients.
    Baraniak I; Kern F; Holenya P; Griffiths P; Reeves M
    J Infect Dis; 2019 Jun; 220(2):228-232. PubMed ID: 30815685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Strain-Specific Neutralizing Epitope on Glycoprotein H of Human Cytomegalovirus.
    Thomas M; Kropff B; Schneider A; Winkler TH; Görzer I; Sticht H; Britt WJ; Mach M; Reuter N
    J Virol; 2021 Aug; 95(18):e0065721. PubMed ID: 34160252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.
    Kirchmeier M; Fluckiger AC; Soare C; Bozic J; Ontsouka B; Ahmed T; Diress A; Pereira L; Schödel F; Plotkin S; Dalba C; Klatzmann D; Anderson DE
    Clin Vaccine Immunol; 2014 Feb; 21(2):174-80. PubMed ID: 24334684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dominant Antiviral CD8
    Pardieck IN; van Duikeren S; Veerkamp DMB; Brasem DJ; Redeker A; van Bergen J; Han W; Ossendorp F; Zondag G; Arens R
    Front Immunol; 2022; 13():680559. PubMed ID: 35154089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step.
    Ye X; Su H; Wrapp D; Freed DC; Li F; Yuan Z; Tang A; Li L; Ku Z; Xiong W; Jaijyan D; Zhu H; Wang D; McLellan JS; Zhang N; Fu TM; An Z
    PLoS Pathog; 2020 Aug; 16(8):e1008736. PubMed ID: 32745149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
    Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
    J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines.
    Wang JB; Adler SP; Hempfling S; Burke RL; Duliège AM; Starr SE; Plotkin SA
    J Infect Dis; 1996 Aug; 174(2):387-92. PubMed ID: 8699071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.
    Cui X; Cao Z; Wang S; Lee RB; Wang X; Murata H; Adler SP; McVoy MA; Snapper CM
    Vaccine; 2018 Sep; 36(37):5580-5590. PubMed ID: 30082162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection.
    Goodwin ML; Webster HS; Wang HY; Jenks JA; Nelson CS; Tu JJ; Mangold JF; Valencia S; Pollara J; Edwards W; McLellan JS; Wrapp D; Fu TM; Zhang N; Freed DC; Wang D; An Z; Permar SR
    Virology; 2020 Sep; 548():182-191. PubMed ID: 32838941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies.
    Pötzsch S; Spindler N; Wiegers AK; Fisch T; Rücker P; Sticht H; Grieb N; Baroti T; Weisel F; Stamminger T; Martin-Parras L; Mach M; Winkler TH
    PLoS Pathog; 2011 Aug; 7(8):e1002172. PubMed ID: 21852946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
    Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing and ELISA IgG antibodies to human cytomegalovirus glycoprotein complexes may help date the onset of primary infection in pregnancy.
    Lilleri D; Gerna G; Furione M; Zavattoni M; Spinillo A
    J Clin Virol; 2016 Aug; 81():16-24. PubMed ID: 27289427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types.
    Kauvar LM; Liu K; Park M; DeChene N; Stephenson R; Tenorio E; Ellsworth SL; Tabata T; Petitt M; Tsuge M; Fang-Hoover J; Adler SP; Cui X; McVoy MA; Pereira L
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1558-68. PubMed ID: 25534746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.